Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 4
Abstract
Background. Carvedilol appears to be more effective than propranolol in the treatment of portal hypertension in cirrhotic patients. Aim. To compare the effects of carvedilol vs. propranolol on systemic and splanchnic haemodynamics and to evaluate the adverse events associated with these treatments. Material and methods. We performed a systematic review following the Cochrane and PRISMA recommendations. Randomised controlled trials comparing carvedilol versus propranolol, in the treatment of portal hypertension in cirrhotic patients with oesophageal varices, with or without bleeding history were included. The primary outcome measure was the haemodynamic response to treatment. Results. Four randomised trials and 153 patients were included; 79 patients received carvedilol (6.25-50 mg/d) and 74 patients received propranolol (10-320 mg/d). The hepatic vein pressure gradient (HVPG) decreased more with carvedilol than with propranolol (MD –2.21; 95% CI: –2.83 to –1.60, I2 = 0%, P < 0.00001). Carvedilol was superior to propranolol for reducing HVPG by ≥ 20% from the baseline value or to ≤ 12 mmHg (OR: 2.93; 95% CI: 1.50 to 5.74, I2 = 22%, P = 0.002). Overall adverse events did not differ between. In conclusion, there is limited evidence suggesting that carvedilol is more effective than propranolol for improving the haemodynamic response in cirrhotic patients with portal hypertension. Long-term randomized controlled trials are needed to confirm this information.
Authors and Affiliations
Nancy Aguilar-Olivos, Miguel Motola-Kuba, Roberto Candia, Marco Arrese, Nahúm Méndez-Sánchez, Misael Uribe, Norberto C Chávez-Tapia
Keywords
Related Articles
- EP ID EP78420
- DOI -
- Views 115
- Downloads 0
Risk and Prognosis of Acute Liver Injury Among Hospitalized Patients with Hemodynamic Instability: A Nationwide Analysis
Risk and Prognosis of Acute Liver Injury Among Hospitalized Patients with Hemodynamic Instability: A Nationwide Analysis Introduction and aim. Critically ill patients in states of circulatory failure are at risk of acute...
Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant
Background and aims. Pegylated interferon (Peg-INF) and ribavirin (RBV) based therapy is suboptimal and poorly tolerated. We evaluated the safety, tolerability and efficacy of a 24-week course of sofosbuvir plus daclata...
Cardiac metastasis of hepatocellular carcinoma in a young non-cirrhotic patient, to the left ventricle
Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver. 1,2 The most common extrahepatic metastatic sites are lung, abdominal lymph nodes and bone, while its cardiac metastasis is rare. 2,3Metasta...
Latin American Association for the Study of the Liver Practice Guidelines Diagnosis, management, and treatment of hepatitis C This document has been approved by the Latin American Association for the Study of the Liver (ALEH)
Annals of Hepatology: Viewpoints from Afar
-